MET and hereditary leiomyomatosis and renal cell cancer: Recent discoveries revealed activating mutations in MET oncogene and inactivating mutation in Fumarate Hydratase (FH) gene in the hereditary papillary renal carcinoma (HPRC) and hereditary leiomyomatosis and renal-cell cancers (HLRCC), respectively.